Treatment and Vaccination for Smallpox and Monkeypox
- PMID: 38801586
- DOI: 10.1007/978-3-031-57165-7_19
Treatment and Vaccination for Smallpox and Monkeypox
Abstract
The smallpox infection with the variola virus was one of the most fatal disorders until a global eradication was initiated in the twentieth century. The last cases were reported in Somalia 1977 and as a laboratory infection in the UK 1978; in 1980, the World Health Organization (WHO) declared smallpox for extinct. The smallpox virus with its very high transmissibility and mortality is still a major biothreat, because the vaccination against smallpox was stopped globally in the 1980s. For this reason, new antivirals (cidofovir, brincidofovir, and tecovirimat) and new vaccines (ACAM2000, LC16m8 and Modified Vaccine Ankara MVA) were developed. For passive immunization, vaccinia immune globulin intravenous (VIGIV) is available. Due to the relationships between orthopox viruses such as vaccinia, variola, mpox (monkeypox), cowpox, and horsepox, the vaccines (LC16m8 and MVA) and antivirals (brincidofovir and tecovirimat) could also be used in the mpox outbreak with positive preliminary data. As mutations can result in drug resistance against cidofovir or tecovirimat, there is need for further research. Further antivirals (NIOCH-14 and ST-357) and vaccines (VACΔ6 and TNX-801) are being developed in Russia and the USA. In conclusion, further research for treatment and prevention of orthopox infections is needed and is already in progress. After a brief introduction, this chapter presents the smallpox and mpox disease and thereafter full overviews on antiviral treatment and vaccination including the passive immunization with vaccinia immunoglobulins.
Keywords: Brincidofovir; Immunoglobulins; Monkeypox; Mpox; Orthopox; Smallpox; Tecovirimat; Vaccinia; Variola; Virokines.
© 2024. The Author(s), under exclusive license to Springer Nature Switzerland AG.
Similar articles
-
Exploring the Potential Treatment for Mpox.Acta Med Indones. 2024 Jul;56(3):400-408. Acta Med Indones. 2024. PMID: 39463117 Review.
-
Poxvirus Vaccines: Past, Present, and Future.Adv Exp Med Biol. 2024;1451:273-287. doi: 10.1007/978-3-031-57165-7_17. Adv Exp Med Biol. 2024. PMID: 38801584 Review.
-
Therapeutic strategies for human poxvirus infections: Monkeypox (mpox), smallpox, molluscipox, and orf.Travel Med Infect Dis. 2023 Mar-Apr;52:102528. doi: 10.1016/j.tmaid.2022.102528. Epub 2022 Dec 17. Travel Med Infect Dis. 2023. PMID: 36539022 Free PMC article. Review.
-
Therapeutic agents for the treatment of human mpox.Curr Opin Infect Dis. 2024 Dec 1;37(6):518-525. doi: 10.1097/QCO.0000000000001069. Epub 2024 Oct 9. Curr Opin Infect Dis. 2024. PMID: 39382085 Review.
-
Treatment with the smallpox antiviral tecovirimat (ST-246) alone or in combination with ACAM2000 vaccination is effective as a postsymptomatic therapy for monkeypox virus infection.Antimicrob Agents Chemother. 2015 Jul;59(7):4296-300. doi: 10.1128/AAC.00208-15. Epub 2015 Apr 20. Antimicrob Agents Chemother. 2015. PMID: 25896687 Free PMC article.
References
-
- Adler H, Gould S, Hine P, Snell LB, Wong W, Houlihan CF, Osborne JC, Rampling T, Beadsworth MBJ, Duncan CJA, Dunning J, Fletcher TE, Hunter ER, Jacobs M, Khoo SH, Newsholme W, Porter D, Porter RJ, Ratcliffe L, Schmid ML, Semple MG, Tunbridge AJ, Wingfield T, Price NM (2022) Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect Dis 22:1153–1162. https://doi.org/10.1016/S1473-3099(22)00228-6 - DOI - PubMed - PMC
-
- Andrei G, Snoeck R (2010) Cidofovir activity against poxvirus infections. Viruses 2:2803–2830. https://doi.org/10.3390/v2122803 - DOI - PubMed - PMC
-
- CDC (2022a) Expanded Access IND Protocol: use of tecovirimat (TPOXX®) for treatment of human non-variola orthopoxvirus infections in adults and children (IND No. 116,039). Centers for Disease Control and Prevention, United States. https://www.cdc.gov/poxvirus/monkeypox/pdf/tecovirimat-ind-protocol-cdc-... . Accessed: 2 Jan 2023
-
- CDC (2022b) Expanded Access IND Protocol: Use of Vaccinia Immune Globulin Intravenous (VIGIV, CNJ-016) for treatment of human Orthopoxvirus infection in adults and children (BB-IND No. 10788). Centers for Disease Control and Prevention, United States. https://www.cdc.gov/poxvirus/monkeypox/pdf/vigiv-ind-protocol.pdf . Accessed: 2 Jan 2023
-
- ECDC (2023) Mpox (formerly named monkeypox) situation update, as of 3 January 2022. European Centre for Disease Prevention and Control (ECDC), Stockholm. https://www.ecdc.europa.eu/en/news-events/monkeypox-situation-update . Accessed: 4 Jan 2023
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous